+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Impact of preprocedural high-sensitivity C-reactive protein levels on uncovered stent struts: an optical coherence tomography study after drug-eluting stent implantation



Impact of preprocedural high-sensitivity C-reactive protein levels on uncovered stent struts: an optical coherence tomography study after drug-eluting stent implantation



Clinical Cardiology 34(2): 97



There are no sufficient data to evaluate the relationship between high-sensitivity C-reactive protein (hs-CRP) and uncovered stent struts on optical coherence tomography (OCT) after drug-eluting stent (DES) implantation. We evaluated the relationship between the preprocedural level of hs-CRP and incomplete neointimal coverage of DES struts on OCT. This study was conducted using 124 eligible patients (132 lesions) treated with sirolimus-eluting stents (SES) or zotarolimus-eluting stents (ZES). The subjects were divided into 2 groups based on the preprocedural hs-CRP level: high-CRP (≥3 mg/L; 58 lesions) and normal-CRP (<3 mg/L, 74 lesions) groups. The percentage of uncovered struts, calculated as the ratio of uncovered struts to total struts in all OCT cross-sections, was compared between the 2 groups according to initial clinical presentation (stable angina [SA] vs acute coronary syndrome) and the type of implanted DES (SES vs ZES). There was no significant correlation between hs-CRP and the percentage of uncovered struts on OCT in all enrolled lesions. In the SA subgroup, the percentage of uncovered struts was significantly higher in the high-CRP group than in the normal-CRP group (8.1 ± 11.6% vs 3.8 ± 7.9%, P = 0.018). There was significant correlation between hs-CRP level and the percentage of uncovered struts in SA patients with SES (r = 0.280, P = 0.039), but not ZES (r = - 0.063, P = 0.729). Preprocedural hs-CRP level could affect incomplete neointimal coverage of struts after DES implantation depending on the initial clinical presentation and the type of implanted DES.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 053722472

Download citation: RISBibTeXText

PMID: 21298653

DOI: 10.1002/clc.20856


Related references

Major determinants for the uncovered stent struts on optical coherence tomography after drug-eluting stent implantation. International Journal of Cardiovascular Imaging 28(4): 705-714, 2012

Optical coherence tomography derived cut-off value of uncovered stent struts to predict adverse clinical outcomes after drug-eluting stent implantation. International Journal of Cardiovascular Imaging 29(6): 1255-1263, 2013

Rationale and study design of the OISTER trial: optical coherence tomography evaluation of stent struts re-endothelialization in patients with non-ST-elevation acute coronary syndromes--a comparison of the intrEpide tRapidil eluting stent vs. taxus drug-eluting stent implantation. Journal of Cardiovascular Medicine 11(7): 536-543, 2010

Long-term follow-up evaluation after sirolimus-eluting stent implantation by optical coherence tomography: do uncovered struts persist?. Journal of the American College of Cardiology 51(9): 968-969, 2008

Prognostic Impact of 9-Month High-Sensitivity C-Reactive Protein Levels on Long-Term Clinical Outcomes and In-Stent Restenosis in Patients at 9 Months after Drug-Eluting Stent Implantation. Plos one 10(9): E0138512, 2015

Prognostic impact of preprocedural C reactive protein levels on 6-month angiographic and 1-year clinical outcomes after drug-eluting stent implantation. Heart 93(9): 1087-1092, 2007

AS-154: Prognostic Impact of Preprocedural Levels of C-Reactive Protein, Lipoprotein(a) and Homocysteine on the Long-Term Clinical Outcomes in Patients with Drug-Eluting Stent Implantation. American Journal of Cardiology 105(9-Supp-S): 66-0, 2010

Serial optical coherence tomography assessment of malapposed struts after everolimus-eluting stent implantation. A subanalysis from the HEAL-EES study. Cardiovascular Revascularization Medicine 18(1): 47-52, 2016

Favorable neointimal coverage in everolimus-eluting stent at 9 months after stent implantation: comparison with sirolimus-eluting stent using optical coherence tomography. International Journal of Cardiovascular Imaging 28(3): 491-497, 2012

TCTAP C-234 Very Late Stent Thrombosis Caused by Obvious Very Late Acquired Stent Malapposition Assessed by Optical Coherence Tomography After Everolimus-eluting Stent Implantation into Sirolimus-eluting Stent. Journal of the American College of Cardiology 67(16): S387-S388, 2016

Optical coherence tomography findings of very late stent thrombosis after drug-eluting stent implantation. International Journal of Cardiovascular Imaging 28(4): 715-723, 2012

Evaluation of the late stent malposition after drug-eluting stent implantation by optical coherence tomography. Zhonghua Xin Xue Guan Bing Za Zhi 37(7): 585-589, 2009

The differences of neointimal coverage among bare-metal stent, zotarolimus-eluting stent and everolimus-eluting stent at 9 Months after implantation using optical coherence tomography in STEMI patents. European Heart Journal 34(Suppl 1): P5492-P5492, 2013

Analysis of optical coherence tomography of early and very late stent restenosis after drug-eluting stent implantation. Zhonghua Yi Xue Za Zhi 97(23): 1778-1783, 2017

Mechanisms of very late stent thrombosis after drug-eluting stent implantation: findings from coronary angioscopy and optical coherence tomography. Jacc. Cardiovascular Imaging 4(11): 1217-1219, 2011